Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telavancin versus standard intravenous therapy for Staphylococcus aureus bacteremia including infective endocarditis
RBR-3p8g7nPhase 3Recruiting
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telavancin in Staphylococcal bacteremia and endocarditis (IE) (2 arms), sponsored by Instituto Dante Pazzanese de Cardiologia. Started Jun 2015; status: recruiting.
02
Drugs
telavancin
03
Conditions
Staphylococcal bacteremiaendocarditis (IE)
Beyond the preview
Go deeper on RBR-3p8g7n.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3p8g7n.